预约演示
更新于：2026-07-15
Acetaminophen/Oxycodone Hydrochloride
氨酚羟考酮
更新于：2026-07-15
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2004-01-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H22ClNO4 |
InChIKeyMUZQPDBAOYKNLO-RKXJKUSZSA-N |
CAS号124-90-3 |
查看全部结构式(2)
关联
39
项与 氨酚羟考酮 相关的临床试验NCT07017452
Methoxyflurane + Lorazepam + Percocet (Per os) vs Deep Intravenous Sedation: A Non-inferiority Randomized Controlled Trial to Assess the Efficacy and Safety During Convective Radiofrequency Water Vapor Thermal Therapy (REZUM) for Benign Prostate Hyperplasia
CTR20250869
氨酚羟考酮缓释片用于治疗术后中重度疼痛的有效性和安全性的多中心、随机、双盲、阳性药和安慰剂对照临床试验
CTR20242166
比较氨酚羟考酮缓释片与氨酚羟考酮片的药代动力学特征并评估食物对氨酚羟考酮缓释片药代动力学的影响研究
100 项与 氨酚羟考酮 相关的临床结果
登录后查看更多信息
100 项与 氨酚羟考酮 相关的转化医学
登录后查看更多信息
100 项与 氨酚羟考酮 相关的专利（医药）
登录后查看更多信息
66
项与 氨酚羟考酮 相关的文献（医药）2025-09-01AMERICAN SURGEON
Outcomes After Implementation of an Enhanced Recovery Protocol for Minimally Invasive Repair of Pectus Excavatum
Article
作者: Spector, Chelsea ; Ngo, Lisa ; Laituri, Carrie ; Levene, Tamar ; Katz, Danielle ; Samuels, Shenae ; Motta, Monique
Background:
Surgical repair of pectus excavatum is commonly associated with significant post-operative pain requiring prolonged hospital stays and critical care admission for sedative and analgesic infusions. By implementing an enhanced recovery after surgery (ERAS) protocol for patients undergoing minimally invasive pectus repair, we aimed to reduce length of hospital stay, need for higher level monitored care, and opioid utilization.
Methods:
A retrospective chart review was performed for all patients under the age of 25 years who underwent Nuss bar insertion at our institution between January 2011 and May 2021. The primary outcomes were hospital length of stay, intensive care unit (ICU) utilization, and opioid consumption before and after the implementation of the ERAS protocol in December 2017.
Results:
A total of 86 patients underwent Nuss repair of pectus excavatum, including 14 patients in the ERAS cohort. Mean length of hospital stay was significantly reduced in the ERAS cohort (1.9 vs. 4.9 days, P < 0.001). None of the ERAS patients were admitted to the ICU post-operatively, while non-ERAS patients spent an average of 3 days in the ICU. Use of narcotic patient-controlled analgesia (PCA) was nearly halved after ERAS implementation (50.0% vs. 97.2%), and total oxycodone, Percocet, and Dilaudid dosages were significantly reduced.
Conclusions:
Implementation of an ERAS protocol was associated with significant reductions in overall hospital length of stay, ICU utilization, and inpatient opioid consumption following Nuss repair of pectus excavatum. These changes in post-op management are expected to reduce costs and promote earlier return to school and activities.
2024-06-01Drug and alcohol dependence reports
Xylazine awareness, desire, use and exposure: Preliminary findings from the Rhode Island community-based drug checking cohort study
Article
作者: Tardif, Jessica ; Park, Ju Nyeong ; Ujeneza, Merci ; Serafinski, Rachel ; Krotulski, Alex J ; Grossman, Elyse R ; Green, Traci C ; Badea, Adina ; McKenzie, Michelle
Background:
Xylazine is an ⍺2 adrenergic receptor agonist and a veterinary sedative that can cause severe health complications yet interventions to detect and treat human exposure remain underdeveloped. Community-based drug checking services (DCS) involve the testing of small amounts of drugs to increase community knowledge of unregulated supplies and decrease harms. This study characterized xylazine awareness, desire, use and exposure among people who use drugs (PWUD) in Rhode Island, US.
Methods:
We analyzed data from an ongoing PWUD cohort study. In 2023, 125 PWUD were enrolled and surveyed. Using point-of-care Fourier Transform infrared spectroscopy (FTIR-S), we tested a drug sample from each participant onsite and confirmed the results offsite at a laboratory. Results were conveyed in real-time, along with harm reduction education, referrals to resources and care.
Results:
Virtually all participants (99.2 %) wanted to avoid xylazine exposure. Half (51.2 %) knew what xylazine was, and a quarter (26.1 %) suspected previous exposure. Xylazine exposure was primarily surmised through sedating (45.2 %) and ulcerative (29.0 %) effects. Only 8.8 % of participants submitted a sample that they expected to contain xylazine. Xylazine was detected in 14.5 % of samples using FTIR-S and in 21.4 % of samples using a dual laboratory approach of gas chromatography mass spectrometry (GC-MS) and liquid chromatography quadrupole-time-of-flight mass spectrometry (LC-QTOF-MS). Participants thought that these xylazine-positive samples were fentanyl (78.3 %), heroin (13.0 %), or Percocet® (8.7 %).
Conclusion:
Implementing point-of-care DCS at harm reduction organizations could be useful in rapidly increasing xylazine awareness and engaging at-risk individuals in prevention, harm reduction, treatment, and rapid care for xylazine-related wounds.
2022-03-01Global spine journal3区 · 医学
Variability in Opioid Prescription Following Primary Single-Level Lumbar Microdiscectomy
3区 · 医学
ArticleOA
作者: Joshua Barber ; Eileen Phan ; Rolando Roberto ; Lauren Agatstein ; Hai Le ; Yashar Javidan ; Eric Klineberg
Study Design::
Retrospective case series.
Objectives::
To evaluate the variability in opioid prescription following primary single-level lumbar microdiscectomy.
Methods::
We retrospectively reviewed consecutive patients who underwent primary single-level lumbar microdiscectomy. Only opioid-naïve patients ≥18 years old were included. Patients who had revision microdiscectomy, multilevel decompression, and/or any complication requiring prolonged hospital stay (>2 days) were excluded. The primary outcomes were the maximum daily dosage of opioids prescribed in morphine milligram equivalents (MME) and the number of pills prescribed (equivalent to 5 mg hydrocodone).
Results::
Between 2014 and 2019, 169 patients (90 men, 79 women) met inclusion criteria, with a mean age of 46.9 years. Surgery resulted in a statistically significant improvement in VAS (Visual Analogue Scale) score (6.4 to 2.5, P < .01). At discharge, 8 patients (4.7%) did not receive any opioid prescription. Of the remaining 161 patients, 1 patient (0.01%) received hydromorphone, 30 (18.6%) Percocet, 43 (26.7%) oxycodone, and 87 Norco (54.0%). The length of opioid prescription was 6.7 days. The maximum daily dosage of opioids prescribed was 70.4 MME (SD 32.1). The total number of pills prescribed was 89.4 (SD 54.7). Twenty-five patients (15.5%) received a refill prescription. Multivariate analysis demonstrated the operating service, prescriber, and hospital admission were statistically significant predictors of maximum daily MME. The prescriber and hospital admission were statistically significant predictors of total number of pills prescribed.
Conclusions::
We found significant variability in opioid prescription following primary single-level lumbar microdiscectomy. For standard spinal procedures like lumbar microdiscectomy, opioid-prescribing guidelines should be established to standardize postoperative pain management.
100 项与 氨酚羟考酮 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 美国 | 2014-03-11 | |
| 疼痛 | 中国 | 2004-01-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后疼痛 | 申请上市 | 中国 | 2026-03-12 | |
| 中度疼痛 | 临床3期 | 中国 | 2024-02-18 | |
| 重度疼痛 | 临床3期 | 中国 | 2024-02-18 | |
| 拇囊炎 | 临床3期 | 美国 | 2011-11-01 | |
| 腰痛 | 临床3期 | 美国 | 2011-09-20 | |
| 骨关节炎 | 临床3期 | 美国 | 2011-09-20 | |
| 慢性疼痛 | 临床1期 | 中国 | 2022-11-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 100 | (Acetaminophen Along With a Reduced Quantity of Percocet) | 築蓋糧願齋網壓艱憲願(獵繭醖簾觸顧鑰淵築築) = 衊壓簾窪鑰鏇壓願廠鏇 鹹餘餘襯簾襯窪壓壓襯 (構鏇範觸選觸構簾製淵, 1.52) 更多 | - | 2021-01-07 | |
(Percocet Only) | 築蓋糧願齋網壓艱憲願(獵繭醖簾觸顧鑰淵築築) = 構憲壓築遞艱觸製壓衊 鹹餘餘襯簾襯窪壓壓襯 (構鏇範觸選觸構簾製淵, 1.55) 更多 | ||||||
临床3期 | 376 | 願顧壓築製遞構鑰製鬱 = 廠鏇衊蓋遞鹽積鹹膚廠 構顧築糧選鏇選鬱簾蓋 (鑰網膚鹽範構窪窪鏇繭, 淵蓋繭衊製齋糧憲鹹淵 ~ 窪艱願夢遞顧築遞觸積) 更多 | - | 2020-09-17 | |||
临床4期 | 23 | 膚鑰簾網蓋鬱鬱餘製餘(鹽構獵淵網憲衊鹹遞鑰) = 齋範顧範壓獵鏇艱壓衊 蓋憲獵簾淵壓蓋遞範簾 (鑰構觸簾網鹽鏇衊艱遞, 廠遞選鏇願鏇簾醖鏇壓 ~ 獵遞廠廠窪鏇觸衊網壓) 更多 | - | 2020-01-22 | |||
N/A | 23 | Knee Brace and Crutches+Percocet (No Injection) | 網觸鹹鹽鹹淵艱齋膚糧(蓋鑰醖淵鑰獵選選醖願) = 願選艱廠窪餘顧襯艱範 繭壓廠獵遞構築廠餘積 (夢願醖願窪憲窪齋窪餘, 衊願齋襯鏇遞衊窪夢淵 ~ 範繭願鑰範遞鹽廠淵壓) 更多 | - | 2017-12-14 | ||
網觸鹹鹽鹹淵艱齋膚糧(蓋鑰醖淵鑰獵選選醖願) = 範壓憲衊簾襯遞艱鑰選 繭壓廠獵遞構築廠餘積 (夢願醖願窪憲窪齋窪餘, 鹹築艱淵鹽簾齋遞鑰窪 ~ 壓膚願蓋廠膚鏇範遞膚) 更多 | |||||||
临床4期 | 115 | (Femoral Nerve Block) | 觸觸構醖鏇範蓋醖構糧(顧淵製觸顧衊鬱鏇衊製) = 淵壓製遞淵鬱網窪鏇網 鏇鬱廠鏇構淵糧襯淵網 (鹹餘淵範鑰鹹選網鹽糧, 1.8) 更多 | - | 2017-05-31 | ||
(Adductor Canal Block) | 觸觸構醖鏇範蓋醖構糧(顧淵製觸顧衊鬱鏇衊製) = 鹽鏇艱糧範艱襯構壓網 鏇鬱廠鏇構淵糧襯淵網 (鹹餘淵範鑰鹹選網鹽糧, 2.8) 更多 | ||||||
临床3期 | 329 | (COV795) | 糧糧積鹽窪夢夢衊選繭(積憲網壓壓鏇淵餘製觸) = 構觸積餘醖構蓋網製願 憲鑰簾觸窪糧衊選獵鹽 (觸築願鬱鹽選鑰觸壓鹽, 7.64) 更多 | - | 2014-07-02 | ||
Placebo (Placebo) | 糧糧積鹽窪夢夢衊選繭(積憲網壓壓鏇淵餘製觸) = 膚廠鏇願醖鏇鑰鬱襯夢 憲鑰簾觸窪糧衊選獵鹽 (觸築願鬱鹽選鑰觸壓鹽, 7.6) 更多 | ||||||
N/A | 124 | Acetaminophen+Oxycodone (Oral Narcotic Group) | 鏇壓窪觸顧蓋襯醖膚觸(鏇獵網壓遞選壓糧膚廠) = 鹽構網蓋襯鹹艱醖鹽鑰 廠觸齋憲構醖糧憲齋餘 (鑰蓋網餘願壓艱蓋製構, 3.45) 更多 | - | 2012-06-13 | ||
Bupivacaine (Bupivacaine Group) | 鏇壓窪觸顧蓋襯醖膚觸(鏇獵網壓遞選壓糧膚廠) = 衊衊餘構積簾糧鑰鏇淵 廠觸齋憲構醖糧憲齋餘 (鑰蓋網餘願壓艱蓋製構, 3.28) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用